Metabolism and cancer: An up-to-date review of a mutual connection

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1437-1444

  Mentis, Alexios Fotios A ^a   Kararizou, Evangelia ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cancer; Carcinogenesis; Genes; Glucose; Metabolism

Indexed keywords

EID: 79956123670     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (96)

1. Allison SJ, Milner J (2007). SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle, 6, 2669-77.
2. Aoki T, Weber G (1981). Carbamoyl phosphate synthetase (glutamine-hydrolyzing): increased activity in cancer cells. Science, 212, 463-5.
3. Aykin-Burns N, Ahmad IM, Zhu Y, et al (2009). Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J, 418, 29-37.
4. Biamonti G, Caceres JF (2009). Cellular stress and RNA splicing. Trends Biochem Sci, 34, 146-53.
5. Boily G, He XH, Pearce B, et al (2009). SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene, 28, 2882-93.
6. Cannito S, Novo E, Compagnone A, et al (2008). Redox mechanisms switch on hypoxia-dependent epithelialmesenchymal transition in cancer cells. Carcinogenesis, 29, 2267-78.
7. Cantó C, Auwerx J (2009). Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab, 20, 325-31.
8. Cantó C, Gerhart-Hines Z, Feige JN, et al (2009). AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 458, 1056-60.
9. Cervera AM, Apostolova N, Crespo FL, et al (2008). Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res, 68, 4058-67.
10. Choi MM, Kim EA, Huh JW, et al (2008). Small-interfering-RNA-mediated silencing of human glutamate dehydrogenase induces apoptosis in neuroblastoma cells. Biotechnol Appl Biochem, 51, 107-10.
11. Christofk HR, Vander Heiden MG, Harris MH, et al (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452, 230-3(a).
12. Christofk HR, Vander Heiden MG, Wu N, et al (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 452, 181-6(b).
13. Corriden R, Insel PA (2010). Basal release of ATP: an autocrineparacrine mechanism for cell regulation. Sci Signal, 3, 1.
14. Dang CV. Different View of the Warburg (2009). Effect PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the warburg effect. Sci Signal, 2, 75.
15. Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-44.
16. Darling PB, Grunow J, Rafii M, et al (2000). Threonine dehydrogenase is a minor degradative pathway of threonine catabolism in adult humans. Am J Physiol Endocrinol Metab, 278, E877-84.
17. David CJ, Chen M, Assanah M, et al (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 463, 364-9.
18. Deng CX (2009). SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci, 5, 147-52.
19. Denkert C, Budczies J, Weichert W, et al (2008). Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer, 7, 72.
20. Drygin D, Siddiqui-Jain A, O'Brien S, et al (2009). Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res, 69, 7653-61.
21. Edgar AJ (2002). The human L-threonine 3-dehydrogenase gene is an expressed pseudogene. BMC Genet, 3, 18.
22. Escande C, Chini CCS, Nin V, et al (2010). Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high fat diet-induced liver steatosis in mice. J Clin Invest 1, 120, 545-58.
23. Fantin VR, St-Pierre J, Leder P (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-34.
24. Ferguson EC, Rathmell JC (2008). New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci, 33, 359-62.
25. Firestein R, Blander G, Michan S, et al (2008). The SIRT1 deacetylase suppresses intestinal tumourigenesis and colon cancer growth. PLoS One, 3, e2020.
26. Ford E, Voit R, Liszt G, et al (2006). Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev, 20, 1075-80.
27. Frederiks WM, Vizan P, Bosch KS, et al (2008). Elevated activity of the oxidative and non-oxidative pentose phosphate pathway in (pre)neoplastic lesions in rat liver. Int J Exp Pathol, 89, 232-40.
28. Funasaka T, Hogan V, Raz A (2009). Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res, 69, 5349-56.
29. Funasaka T, Hu H, Yanagawa T, et al (2007). Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res, 67, 4236-43.
30. Funasaka T, Yanagawa T, Hogan V, et al (2005). Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J, 19, 1422-30.
31. Furuta E, Okuda H, Kobayashi A, et al (2010). Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta, 1805, 141-52.
32. Gupta PB, Chaffer CL, Weinberg RA (2009). Cancer stem cells: mirage or reality? Nat Med, 15, 1010-2.
33. Haigis MC, Mostoslavsky R, Haigis KM, et al (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell, 126, 941-54.
34. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
35. Hao HX, Khalimonchuk O, Schraders M, et al (2009). SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 325, 1139-42.
36. Hitosugi T, Kang S, Vander Heiden MG, et al (2009). Tyrosine phosphorylation inhibits PKM2 to promote the warburg effect and tumor growth. Sci Signal, 2, ra73.
37. Hsu PP, Sabatini DM (2008). Cancer cell metabolism: warburg and beyond. Cell, 134, 703-7.
38. Ishikawa K, Takenaga K, Akimoto M, et al (2008). ROSgenerating mitochondrial DNA mutations can regulate tumor cell metastatis. Science, 320, 661-4.
39. Jin S, White E (2008). Tumor suppression by autophagy through the management of metabolic stress. Autophagy, 4, 563-6.
40. Jung-Hynes B, Ahmad N (2009). SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with agerelated neoplasms. FASEB J, 23, 2803-9.
41. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (2009). Targeting MET as a strategy to overcome crosstalkrelated resistance to EGFR inhibitors. Lancet Oncol, 10, 709-17.
42. Kassi E, Papavassiliou AG (2008). Could glucose be a proaging factor? J Cell Mol Med, 12, 1194-8.
43. Kawahara TL, Michishita E, Adler AS, et al (2009). SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 136, 62-74.
44. Kim MJ, Ahn K, Park SH, et al (2009). SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett, 583, 1183-8.
45. Kim MY, Oskarsson T, Acharyya S, et al (2009). Tumor selfseeding by circulating cancer cells. Cell, 139, 1315-26.
46. Lara E, Mai A, Calvanese V, et al (2009). Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 28, 781-91.
47. Lee HC, Wei YH (2009). Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci, 10, 674-701.
48. Lee IH, Cao L, Mostoslavsky R, et al (2008). A role for the NADdependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A, 105, 3374-9.
49. Levine B, Kroemer G (2008). Autophagy in the pathogenesis of disease. Cell, 132, 27-42.
50. Li Y, Bäckesjö CM, Haldosén LA, et al (2009). Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol, 609, 13-8.
51. Lum JJ, Bui T, Gruber M, et al (2007). The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev, 21, 1037-49.
52. Mani SA, Guo W, Liao MJ, et al (2008). The epithelialmesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-15.
53. Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med, 361, 1058-66.
54. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, et al (2009). HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem, 9, 1084-101.
55. Meadows AL, Kong B, Berdichevsky M, et al (2008). Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells. Biotechnol Prog, 24, 334-41.
56. Migita T, Narita T, Nomura K, et al (2008). ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res, 68, 8547-54.
57. Moen I, Øyan AM, Kalland KH, et al (2009). Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One, 4, e6381.
58. Nakagawa T, Lomb DJ, Haigis MC, et al (2009). SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell, 137, 560-70.
59. Narala SR, Allsopp RC, Wells TB, et al (2008). SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell, 19, 1210-9.
60. Nomura DK, Long JZ, Niessen S, et al (2010). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell, 140, 49-61.
61. Nosho K, Shima K, Irahara N, et al (2009). SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol, 22, 922-32.
62. Oberdoerffer P, Michan S, McVay M, et al (2008). SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 135, 907-18.
63. Ogunleye AA, Ogston SA, Morris AD, et al (2009). A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer, 101, 1199-201.
64. Park EJ, Lee JH, Yu GY, et al (2010). Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 140, 197-208.
65. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al (2009). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8, 3984-4001.
66. Qiu Y, Cai G, Su M, et al (2009). Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLCQTOFMS. J Proteome Res, 8, 4844-50.
67. Ruckenstuhl C, Büttner S, Carmona-Gutierrez D, et al (2009). The Warburg effect suppresses oxidative stress induced apoptosis in a yeast model for cancer. PLoS One, 4, e4592.
68. Scatena R, Bottoni P, Pontoglio A, et al (2008). Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs, 17, 1533-45.
69. Schafer ZT, Grassian AR, Song L, et al (2009). Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature, 461, 109-13.
70. Shaw RJ (2006). Glucose metabolism and cancer. Curr Opin Cell Biol, 18, 598-608.
71. Sreekumar A, Poisson LM, Rajendiran TM, et al (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910-4.
72. Telang S, Yalcin A, Clem AL, et al (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene, 25, 7225-34.
73. Thompson CB (2009). Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med, 360, 813-5.
74. Tschudy DP, Welland FH, Collins AR, et al (1964). The effect of tumor growth on hepatic threonine dehydrogenase. Cancer Res, 24, 2033-7.
75. van Leeuwen I, Lain S (2009). Sirtuins and p53. Adv Cancer Res, 102, 171-95.
76. Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33.
77. Vizán P, Alcarraz-Vizán G, Díaz-Moralli S, et al (2009). Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer, 124, 2789-96.
78. Vousden KH, Ryan KM (2009). p53 and metabolism. Nat Rev Cancer, 9, 691-700.
79. Wang J, Alexander P, Wu L, et al (2009). Dependence of mouse embryonic stem cells on threonine catabolism. Science, 325, 435-9.
80. Wang RH, Sengupta K, Li C, et al (2008). Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 14, 312-23.
81. Warburg O (1956). On respiratory impairment in cancer cells. Science, 124, 269-70.
82. Wellen KE, Hatzivassiliou G, Sachdeva UM, et al (2009). ATPcitrate lyase links cellular metabolism to histone acetylation. Science, 324, 1076-80.
83. Yalcin A, Telang S, Clem B, et al (2009). Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol, 86, 174-9.
84. Yan H, Parsons DW, Jin G (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360, 765-73.
85. Yecies JL, Manning BD (2010). Chewing the fat on tumor cell metabolism. Cell, 140, 28-30.
86. Yoshii Y, Furukawa T, Yoshii H (2009). Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism. Cancer Sci, 100, 821-7.
87. Yu J, Auwerx J (2009). The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci, 1173, E10-9.
88. Yu MA, Shin KS, Kim JH, et al (2009). BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol, 20, 567-81.
89. Yu Y, Wan Y, Huang C (2009). The biological functions of NFkappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets, 9, 566-71.
90. Yuan J, Minter-Dykhouse K, Lou Z (2009). A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol, 185, 203-11.
91. Yun J, Rago C, Cheong I, et al (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 325, 1555-9.
92. Yun M, Bang SH, Kim JW, et al (2009). The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med, 50, 1222-8.
93. Zhang Y, Zhou J, Wang T, et al (2007). High level glucose increases mutagenesis in human lymphoblastoid cells. Int J Biol Sci, 3, 375-9.
94. Zhao S, Lin Y, Xu W, et al (2009). Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science, 324, 261-5.
95. Zhao S, Xu W, Jiang W, et al (2010). Regulation of cellular metabolism by protein lysine acetylation. Science, 327, 1000-4.
96. Zhong L, D'Urso A, Toiber D, et al (2010). Histone deacetylase Sirt6 regulates glucose homeostasis via hif1a. Cell, 140, 280-93.